Overview
Tim has led AgomAb Therapeutics as CEO since February 2019 and joined the board in March 2021. Since joining, he has raised a total of $240M and built a broad pipeline focused on growth factor biology and fibrotic indications. Agomab is an argenx spin-off, inheriting strong scientific pedigree from one of Belgium's most important biotech companies.
He holds an executive MBA from IMD Business School, where he was named Valedictorian, and two Master's degrees from Utrecht University. His career includes VP Corporate Development at AM-Pharma, where he led a $600M option-to-buy deal with Pfizer and executed a Phase IIb trial, as well as earlier work as a Senior Associate at Aescap Venture.
Career Highlights
- CEO of Agomab since 2019, raised $240M including a $100M Series C2023
- Named CEO of the Year by European Lifestars; selected as Endpoints 20 under 40 and In Vivo Rising Leader
- Termeer Fellow; IMD Valedictorian
- Former VP Corporate DevelopmentAM-Pharma; led $600M Pfizer option deal
- Former Senior AssociateAescap VentureEuropean medtech VC
Career history
In the news
- Topman biotechbedrijf Agomab: ‘Ik heb moeten leren om grootser te denken’Rust vindt hij in zijn vissersbootje, hengelend naar karpers. Maar als CEO van het Belgische biotechbedrijf Agomab, de chouchou van big pharma en investeerders, wacht de Nederlander Tim Knotnerus een hectische periode met cruciale studieresultaten van kandidaat-medicijnen.
De Tijd Ondernemen · 5 Sept 2026
- Agomab-CEO na rapport Belgische chouchou van big pharma: ‘We staan er beter voor dan ooit’16:09 Na de halfjaarcijfers wacht CEO Tim Knotnerus een cruciale periode met het Belgische biotechbedrijf Agomab, een chouchou van big pharma. Er komen resultaten aan van kandidaat-behandelingen voor chroni...
Related profiles
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.